Charles River Earnings: Cautious Client Spending Affects Near Term, but Long-Term Outlook Positive
Charles River Laboratories reported third-quarter results highlighted by revenue of $1.03 billion, a 4% increase from the prior-year period. The company has experienced pressure from cautious client spending patterns. This has created headwinds for the research models and services segment as biopharma customers have reprioritized pipelines and are conserving cash amid macroeconomic challenges.